Relapsed/refractory multiple myeloma research hub
17 indexed studies · 8 currently recruiting
- authorisedTherapeutic exploratory (Phase II)
Multicenter, open label, phase II clinical trial evaluating the combination of elranatamab with mezigdomide and dexamethasone in patients with relapsed/refractory multiple myeloma
This phase 2 clinical trial looks at a new three-drug combination for adults with multiple myeloma that has returned or stopped responding to treatment. Researchers want to see if combining elranatamab, mezigdomide, and dexamethasone can clear tiny traces of cancer from the bone marrow safely and effectively.
Spain - authorisedTherapeutic exploratory (Phase II)
Phase II, Multicenter, Randomized Study to Evaluate Safety and Efficacy of MRD-guided Therapy with Reduced versus Standard Dose of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (REBEL)
This clinical trial looks at a three-drug combination for multiple myeloma that has returned or stopped responding to treatment. Researchers want to find out if lowering the dose of one drug, belantamab mafodotin, works just as well to control the cancer while causing fewer eye-related side effects.
Poland - recruitingHuman Pharmacology (Phase I)- First administration to humans
A Phase 1 Study of JNJ-87562761 in Relapsed/Refractory Multiple Myeloma
This early-stage study is looking at a new medicine, JNJ-87562761, for people in the UK with multiple myeloma that has come back or hasn't responded to other treatments. It's the first time this drug is being given to humans.
Spain - recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
Phase Ib of Cyclophosphamide, Pomalidomide, Dexamethasone and Daratumumab (CPD-DARA) in patients with relapsed/refractory multiple myeloma. (The CPD-DARA Study).
This study looks at a new combination of medicines (Cyclophosphamide, Pomalidomide, Dexamethasone, and Daratumumab) for people in the UK with multiple myeloma that has come back or isn't responding to treatment. It's a very early stage trial to see if the treatment is safe and how well it's handled by the body.
Ireland - recruitingHuman Pharmacology (Phase I)- Other
To Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination with Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma
This study is looking at a new treatment called XMAB24306, given with an existing medicine called daratumumab. It's for people in the UK who have multiple myeloma that has come back or isn't responding well to other treatments. The main aim is to check if the new combination is safe and how the body handles it.
Norway · Denmark · Spain - authorisedHuman Pharmacology (Phase I)- First administration to humans
A FIRST-IN-HUMAN (FIH) PHASE 1/2 STUDY TO ASSESS SAFETY, TOLERABILITY, AND PRELIMINARY ANTI-TUMOR ACTIVITY OF REGN17372, AN ANTI-GPRC5D X ANTI-CD28 COSTIMULATORY BISPECIFIC MONOCLONAL ANTIBODY, IN COMBINATION WITH LINVOSELTAMAB, AN ANTI-BCMA X ANTI-CD3 BISPECIFIC MONOCLONAL ANTIBODY, IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
This study looks at new drug combinations for multiple myeloma that has come back or not responded to past treatments. It checks how safe they are and if they help shrink the cancer.
Greece - active not recruitingPHASE1
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
This study is testing a new drug, etentamig, along with existing cancer treatments for adults with multiple myeloma that has come back or isn't responding to treatment. We want to see how safe it is and if it helps reduce the disease.
United States · Australia · Germany - recruiting
A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma
This study looks at how treatments for multiple myeloma, a type of blood cancer, work in real life when the disease comes back or doesn't respond to previous treatments. It tracks patient experiences for two years to see how standard care affects them.
Austria · Belgium · France - recruitingPHASE1, PHASE2
A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma
This study is testing two experimental drugs, REGN7945 and linvoseltamab, for advanced multiple myeloma that has come back. We want to see if combining them is safe and helps more than linvoseltamab alone.
Australia · United Kingdom - active not recruitingPHASE1
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets
This study looks at a new drug, ABBV-453, for multiple myeloma that has come back or not responded to previous treatments. Researchers want to see if it's safe, what side effects it might cause, and if it helps to control the disease.
United States · Australia · Israel - authorisedTherapeutic confirmatory (Phase III)
HO183 CAR T: A phase III randomized trial comparing academically produced BCMA-directed CAR T-cells (ARI0002h) with standard of care regimen in patients with relapsed/refractory multiple myeloma
This study compares a new cell therapy (CAR T-cells) with standard treatments for multiple myeloma that has come back or not responded to previous treatments. It aims to see if the new therapy helps people live longer without their cancer getting worse.
Netherlands - authorisedTherapeutic confirmatory (Phase III)
An Open-label, Randomized Phase 3 Study of Linvoseltamab Monotherapy and Linvoseltamab plus Carfilzomib versus Standard of Care Combination Regimens in Patients with Relapsed/Refractory Multiple Myeloma
This study is testing new treatments for a type of blood cancer called multiple myeloma that has come back or isn't responding to previous treatments. It compares new drugs, Linvoseltamab alone or with Carfilzomib, against standard treatments to see how well they work and if they are safe.
Greece · Spain · Poland - authorisedTherapeutic exploratory (Phase II)
A multicenter phase 2 study of Belantamab mafodotin and Mezigdomide in combination with a phase Ib Safety run in patients with relapsed multiple myeloma following BCMA-targeting CAR-T cells or bispecific antibodies. The IFM 2024-01 clinical trial (BELAMI)
This study looks at a new combination treatment for multiple myeloma, a type of blood cancer, in people who have already tried other specific treatments. It aims to see how well the new treatment works and if it's safe. It's for adults whose cancer has returned or didn't respond to previous therapies.
France - recruitingPHASE1, PHASE2
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
This study is testing a new medicine, sonrotoclax, for people in the UK with multiple myeloma that has come back or isn't responding to treatment. Researchers want to see how safe and effective it is, both on its own and with other common myeloma drugs.
United States · Australia · Brazil - recruitingPHASE2
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
This study looks at a new drug, Cemsidomide, combined with Dexamethasone, for people in the UK with multiple myeloma that has come back or isn't responding to other treatments. It aims to see how well the combination works and if it's safe.
United States · United Kingdom - authorisedTherapeutic exploratory (Phase II)
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma (r/r MM)
This study is looking at a new drug, cemsidomide, combined with an existing treatment, dexamethasone, for people with multiple myeloma that has come back or not responded to previous treatments. Researchers want to see how well this new combination works.
Italy · France · Spain - recruitingPHASE3
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
This study compares a new treatment, AZD0120, with standard treatments for multiple myeloma that has come back or isn't responding well. It aims to see if the new medicine works better and is safe for patients.
United States · Australia · Brazil